Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants' Nasopharynx: A Randomized Controlled Trial

Clin Infect Dis. 2020 Dec 15;71(12):3222-3225. doi: 10.1093/cid/ciaa609.

Abstract

In a post hoc analysis of samples from an intrapartum azithromycin randomized clinical trial, we found that children whose mothers had been treated with the drug had higher prevalence of macrolide-resistance genes msr(A) and ermC at 28 days but not at 12 months. The 2 genes were positively associated in the nasopharynx.

Clinical trials registration: NCT1800942.

Trial registration: ClinicalTrials.gov NCT01800942.

Keywords: ermC; msr(A); azithromycin; NPS; The Gambia.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azithromycin* / pharmacology
  • Child
  • Drug Resistance, Bacterial / genetics
  • Humans
  • Infant
  • Macrolides* / pharmacology
  • Nasopharynx
  • Prevalence

Substances

  • Anti-Bacterial Agents
  • Macrolides
  • Azithromycin

Associated data

  • ClinicalTrials.gov/NCT01800942